Norgine Limited

Norgine House, Widewater Place, Moorhall Road, Harefield, Middlesex, UB9 6NS
Telephone: +44 (0)1895 826 600
Fax: +44 (0)1895 825 865
E-mail:
Medical Information e-mail: medinfo@norgine.com


Summary of Product Characteristics last updated on the eMC: 22/03/2011
SPC KLEAN PREP 69g, sachet powder for oral solution


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

KLEAN-PREP 69g, sachet powders for oral solution.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each sachet of KLEAN-PREP contains the following active ingredients:

Macrogol 3350

59.000 g

Anhydrous Sodium Sulphate

5.685 g

Sodium Bicarbonate

1.685 g

Sodium Chloride

1.465 g

Potassium Chloride

0.7425 g

The content of electrolyte ions per sachet when made up to one litre of water is as follows:

Sodium

125 mM

Sulphate

40 mM

Chloride

35 mM

Bicarbonate

20 mM

Potassium

10 mM

For excipients, see 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

A whitish powder which, when dissolved in water, gives a clear, colourless solution for oral administration.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For colonic lavage prior to diagnostic examination or surgical procedures requiring a clean colon, e.g. colonoscopy, barium enema or colonic resection.


Go to top of the page
4.2 Posology and method of administration

Adults: Each sachet should be dissolved in 1 litre of water. The usual dose is up to 4 sachets taken at a rate of 250 ml every 10 to 15 minutes until the total volume is consumed or rectal effluent is clear, or as directed by the physician.

The solutions from all 4 sachets should be drunk within 4 to 6 hours. Alternatively, administration may be divided, for example, taking 2 sachets during the evening before the examination, and the remaining 2 sachets on the morning of the examination.

If administration is by nasogastric tube, the usual rate should be 20 to 30 ml/minute.

Children: There is no recommended dosage.

Renal patients: No dosage adjustment need be made.


Go to top of the page
4.3 Contraindications

Use in patients with known or suspected gastrointestinal obstruction or perforation, ileus, gastric retention, toxic colitis and toxic megacolon.

Congestive cardiac failure (NYHA class III and IV)

Hypersensitivity to any of the ingredients.


Go to top of the page
4.4 Special warnings and precautions for use

No solid food should be eaten for at least 2 hours before taking KLEAN-PREP. The product should only be administered with caution to patients with impaired gag reflex, reflux oesophagitis, or those with diminished levels of consciousness and patients with ulcerative colitis.

Unconscious, semi-conscious patients or patients prone to aspiration or regurgitation should be observed during administration especially if this is via the nasogastric route. There have been reports of pulmonary oedema resulting from aspiration of macrogol lavage solutions requiring immediate treatment.

Although not expected due to the isotonic composition of the product, cases of electrolyte disturbances have been rarely reported in at-risk patients. Therefore, KLEAN-PREP should be used with care in patients at risk of electrolyte disturbance, such as patients with renal failure, mild (NYHA class I and II) congestive cardiac impairment (see also section 4.3), or those simultaneously treated with diuretics.

Should abdominal distension or pain arise, the rate of administration should be slowed down or temporarily stopped until symptoms subside.

KLEAN-PREP contains aspartame, which is metabolised to phenylalanine. This may be harmful for patients with phenylketonuria.

Caution should be used in the administration of KLEAN-PREP to elderly, fragile or debilitated patients.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Oral medication taken within one hour of administration of KLEAN-PREP may be flushed from the gastro-intestinal tract and not absorbed.


Go to top of the page
4.6 Pregnancy and lactation

The preparation should only be used during pregnancy and lactation if considered essential by the physician. There is no experience of use during pregnancy. The purpose and mechanisms of use should be borne in mind if the physician is considering administration.


Go to top of the page
4.7 Effects on ability to drive and use machines

There is no known effect on the ability to drive and use machines.


Go to top of the page
4.8 Undesirable effects

The most commonly experienced undesirable effects are gastrointestinal in nature. The following Adverse Events have been observed in post-marketing experience and therefore the frequencies are not known:

Body System

Adverse Drug reaction

Immune system disorders

Allergic reactions including anaphylactic reaction, dyspnoea, skin reactions (see below)

Metabolism and nutrition disorders

Electrolyte disturbances, specifically hypokalaemia and hyponatraemia These occur more commonly in patients taking concomitant medication affecting the kidneys such as ACE inhibitors and diuretics.

Nervous System Disorders

Convulsions associated with severe hyponatraemia, headaches

Gastrointestinal disorders

Vomiting, nausea, abdominal pain, anorectal discomfort, abdominal distension, flatulence.

Should nausea, vomiting, abdominal pain or distension arise, the rate of administration should be slowed down or stopped until symptoms subside.

Skin and subcutaneous tissue disorders

Allergic skin reactions including angioedema, urticaria, pruritus, rash, erythema.

General disorders and administration site conditions

Rigors

Transient increases in blood pressure have been observed in association with bowel preparations.


Go to top of the page
4.9 Overdose

In case of gross accidental overdosage, where diarrhoea is severe, conservative measures are usually sufficient; generous amounts of fluid, especially fruit juices, should be given.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

ATC Code: A06A D

Macrogol 3350 exerts its effects by virtue of its osmotic effect in the gut, which induces a laxative effect. Electrolytes are present in the formulation and are exchanged across the intestinal barrier (mucosa) with serum electrolytes and water to prevent the occurrence of potential clinically significant variations of net electrolyte or net water balance.

Macrogol 3350 increases the stool volume, which triggers colon motility via neuromuscular pathways. The physiological consequence is an improved propulsive colonic transportation of the softened stools and a facilitation of the defecation.


Go to top of the page
5.2 Pharmacokinetic properties

Macrogol 3350 is unchanged along the gut. It is virtually unabsorbed from the gastro-intestinal tract. Any macrogol 3350 that is absorbed is excreted via the urine.


Go to top of the page
5.3 Preclinical safety data

Preclinical studies provide evidence that macrogol 3350 has no significant systemic toxicity potential.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Vanilla flavour

Aspartame.


Go to top of the page
6.2 Incompatibilities

None are known.


Go to top of the page
6.3 Shelf life

Sachets:

3 years

Solution after reconstitution:

24 hours


Go to top of the page
6.4 Special precautions for storage

Sachets: Store in a dry place. Do not store above 25°C.

Reconstituted solution: Store in a refrigerator (2 – 8°C)


Go to top of the page
6.5 Nature and contents of container

Sachets containing 69gm white powder, in a box of 4 sachets.


Go to top of the page
6.6 Special precautions for disposal and other handling

The solution should be used within 24 hours.


Go to top of the page
ADMINISTRATIVE DATA

Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Norgine Limited

Norgine House

Widewater Place

Moorhall Road

Harefield

UXBRIDGE

Middlesex UB9 6NS

United Kingdom.


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL: 00322/0068.


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

August 1991/March 1997.


Go to top of the page
10. DATE OF REVISION OF THE TEXT

Feb 2011



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/1243/SPC/